Kornimate/medical-research-clean huggingface dataset:
ergon technique versus pnf stretching on hamstring flexibility in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the study will be a randomized control trial and will be conducted in pakistan railway hospital rawalpindi. a sample of 60 participants will be taken. patients will be divided into two groups (a\&b) of 30 participants in each group by sealed envelope method. hot pack will be applied to both groups for 15 minutes at the start of intervention. ergon technique(iastm) will be applied to group a along with strengthening exercise. proprioceptive neuromuscular facilitation (pnf) stretching will be given to group b along with strengthening exercise. a 35 minute session will be given to the patients and 3 sessions will be given once a week. intervention will be given for 6 weeks. the outcome measure will be visual analog scale (vas), western ontario and mcmaster universities arthritis index (womac), and active knee extension test (ake) will be measured at baseline and at the end of 6th week. data will be analyzed by spss 22.


Eligibility criteria:
inclusion criteria: * unilateral/bilateral osteoarthritis * participants with unilateral/bilateral hamstring tightness * 200 from active knee extension test * grade 1 and 2 in kellgren and lawrence criteria for knee osteoarthritis exclusion criteria: * participant failing to fall in the category below will be excluded from the study: * any lower extremity injury in past 3 months * any fracture or surgery done for pelvis, hip or knee. * any neurological symptoms. * any recent knee reconstructive surgery * burns of lower extremities * other musculoskeletal disorders associated with knee joint, iliotibial band, adductor muscle and sartorius muscle tightness

Keywords: knee osteoarthritis ergon technique proprioceptive neuromuscular facilitation stretching active knee extension test western ontario and mcmaster universities arthritis index visual analogue scale
synaptic injury and functional connectivity in alzheimer's disease

Conditions: Alzheimer Disease, Late Onset

Summary: the purpose of this study is to examine cross-sectional associations between csf markers of synaptic injury (ng and snap-25) and functional connectivity in default and semantic memory networks using 3t- fmri in individuals with mci (i.e. the earliest clinically detectable stage of cognitive impairment) due to ad or mild ad dementia (cdr 0.5-1; n=20) and cognitively normal controls (cdr 0; n=20).

specific aims: aim 1: investigate correlations between csf biomarkers of synaptic injury (ng and snap-25) and functional connectivity (fc) within the default mode network (dmn) using resting-state fmri (adjusting for age, gender, apolipoprotein-e4 \[apoe4\] genotype, task performance, and regional brain atrophy) in mci/ad and controls. aim 2: examine correlations between csf biomarkers of synaptic injury and functional connectivity (fc) within the semantic memory network on task-activated fmri using the famous name discrimination task (fndt) (adjusting for age, gender, apoe4 genotype, task performance, and regional brain atrophy) in mci/ad and controls.

Eligibility criteria:
inclusion criteria: participants included in the study should meet all 4 inclusion criteria: 1. 60 years of age or older 2. a clinical diagnosis of mci, mild ad dementia, or normal cognition 3. no significant medical or surgical co-morbidities 4. no contraindications to lp or mri. exclusion criteria: participants with any of the following criteria will be excluded from the study: 1. participants with mci due to ad or mild ad dementia who have been treated with cholinesterase inhibitors or glutamate antagonists in the 3 months prior to study enrollment 2. individuals with any past history of ischemic or traumatic brain injury 3. individuals with imaging evidence of significant cerebrovascular disease or structural brain lesions (e.g. tumor, demyelinating disorders, infection, or congenital anomalies) 4. active mood disorder 5. active alcohol use 6. active use of benzodiazepines, barbiturates, anticholinergic, or anti-epileptic medications

Keywords: synaptic injury
prophylactic benefit of hydroxychloroquine in covid-19 cases with mild to moderate symptoms and in healthcare workers with high exposure risk

Conditions: COVID-19

Summary: few studies have reported the efficacy of hcq in reducing the viral load and improving the severity of symptoms in hospitalized covid-19 cases with serious respiratory infection. however, the prophylactic benefits of hcq has not been clearly defined yet.

this study is designed to evaluate the prophylactic efficacy of hcq in covid-19 cases with mild to moderate symptoms and in the hospital staff engaged in attending infected patients.

Eligibility criteria:
inclusion criteria: * male or female over 18 years of age at the time of enrollment * covid-19 test positive patients with mild-moderate symptoms including fever \>37.50 f * consecutive consenting staff at icu, er and covid-19 unit that have never been diagnosed with covid-19 exclusion criteria: * exclusion criteria: * hepatic cirrhosis or active hepatitis b or c * severe renal disease * hospitalized for severe symptoms of covid-19 (ards), on mechanical ventilation or ecmo * contraindication to hcq * using hcq for some other condition (i.e. sle, rheumatoid arthritis) * pregnant or breast feeding * known history of long qt syndrome (qtc \>500 ms on electrocardiogram) * seizure disorder * body weight \<50kg * psoriasis * unwilling to provide informed consent
sleepiz one+ versus capnography and electrocardiography

Conditions: COPD; Hypertension; Sleep Apnea; Asthma; Heart Diseases; Respiratory Disease

Summary: etco2, or exhaled carbon dioxide, is a non-invasive and commonly used measure for respiratory rate and function. it can be easily monitored using a device called a capnograph, which consists of a sensor that is placed near the patient's mouth or nose and a monitor that displays the concentration of carbon dioxide in the respiratory gases in real-time. etco2 capnography is generally considered a reliable and accurate method for monitoring respiration and is often used as a gold standard for comparing the performance of other methods for measuring respiration. therefore, the primary aim of this study is to provide a thorough comparison of the performance of sleepiz one+ and etco2 capnography for measuring respiration rate, in healthy adults and patients suffering from chronic conditions (e.g. hypertension, copd, asthma, diabetes), at rest in a clinical setting. additionally, the performance of heart rate estimation will be evaluated against ecg.


Eligibility criteria:
inclusion criteria: patients: * age \>=18years * informed consent as documented by signature * one (or more) chronic medical condition/s (e.g., diabetes, asthma, cardiovascular or respiratory diseases, etc.) healthy volunteers * age \>=18years * informed consent as documented by signature * no diagnosed chronic medical condition exclusion criteria: patients * previous enrolment into the current study, * cardiac pacemaker or another implanted electrical device * women who are pregnant or breastfeeding * inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, delirium etc. of the participant healthy volunteers: * previous enrolment into the current study, * cardiac pacemaker or another implanted electrical device * women who are pregnant or breastfeeding * inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, delirium etc. of the participant * presence of diagnosed chronic medical condition
the role of active administration of peristeen bowel evacuation for the management of urinary tract infection

Conditions: Neurogenic Bladder; Neurogenic Bowel; Spina Bifida; Fecal Incontinence; Fecal Impaction; Urinary Incontinence

Summary: this study investigates whether active use of transanal irrigation (peristeen®) effectively manages urinary tract infection among patients with the diagnosis of neurogenic bladder.

this study investigates whether active use of transanal irrigation (peristeen®) effectively manages urinary tract infection among patients diagnosed with neurogenic bladder. it is a prospective exploratory pilot study, and the participants will be asked to perform transanal irrigation twice weekly for 12 weeks (three months). at each visit, including baseline, the study endpoints will be assessed by basic urinalysis, kub imaging, seoul fecal scoring, and a survey (korean neurogenic bowel score).

Eligibility criteria:
inclusion criteria: * between the ages, 5 to 18, and are diagnosed with neurogenic bladder. * use cic (cic: clean intermittent catheterization) daily to empty the bladder. * a recent history of fecal incontinence within the last 3 months * more than two episodes of urinary tract infection and/ or pyuria within the last 6 months exclusion criteria: * an anatomical abnormality of the bladder neck. * known intractable origin of bacteriuria such as urolithiasis (kidney stone) or nonfunctional renal segment. * received bladder augmentation surgery * patient without completion of toilet training * either received following treatment diagnosed according to peristeen® product safety guideline: 1. anorectal malformation 2. colorectal cancer 3. endoscopic polyp removal surgery in 3 months 4. ischemic colitis 5. acute inflammatory bowel disease 6. acute intestinal diverticulum. 7. radiotherapy to the colon 8. long-term corticosteroid usage
facilitating anemia treatment risk communication for patients with kidney disease: decision aid trial

Conditions: Chronic Kidney Disease; End Stage Renal Disease

Summary: anemia is a common complication of chronic kidney disease (ckd). in anemia of chronic kidney disease, patients suffer from low hemoglobin levels, which contribute to feelings of malaise and fatigue. the current accepted practice is often to administer erythropoietin-stimulating agents (esas), which act like the body's natural hormones to stimulate the production of red blood cells from bone marrow. although esas are widely used in ckd, recent evidence suggests that they are not as safe as previously thought. in this study, we seek to test a decision aid to be used when a patient visits his or her nephrologist at vanderbilt. the objective of the decision aid is to reduce patient confusion, improve their satisfaction with their care, improve their knowledge of kidney disease, and ultimately bring more clarity to patients about a controversial but ubiquitous drug. the decision aid will be about 1 page long and will include questions and information that might help the patient be more active and informed regarding the choice of a course of esa therapy. we will ask patients to answer questions before and after their clinic visits regarding their satisfaction and confidence in their treatment and their knowledge of kidney disease; we will ask some of the same questions 3 months after the clinic visit. we will compare patients who are counseled using the decision aid to patients who are not. we anticipate total experiment running time to be approximately 5 months to recruit and follow up on all patients.


Eligibility criteria:
inclusion criteria: * has chronic kidney disease or end stage renal disease * over 18, under 80 years of age * currently receiving care in the vanderbilt nephrology or dialysis clinics * receiving esas for anemia * speaks and can read english (no previous use of interpreter services) * no significant visual impairment documented in medical record exclusion criteria: * diagnosed cognitive disability * stated inability to converse and read fluently in english, or prior use of translation services * poor visual acuity

Keywords: health literacy health numeracy
patient's perception in symptoms related to morning activity based on chronic obstructive lung disease

Conditions: COPD

Summary: the aim of this study is to assess the perception of chronic obstructive pulmonary disease (copd) patients in symptoms related to morning activities. also the researchers investigated how to describe the impact of symptoms on sleep quality and how to use the medication in korea copd treatments.


Eligibility criteria:
inclusion criteria: * copd outpatients over 45 years old * lung function: post-fev1 \< 50% * current or ex-smoker \> 10 packs per year * patients who were not on medication of isc/fc at least 2 weeks exclusion criteria: * ongoing exacerbation of copd or within the previous 3 months * history of asthma or allergic rhinitis * lung cancer or any other significant respiratory disease such as bronchiectasis, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis * current participation in an interventional clinical trial

Keywords: copd symptom morning activity questionnaire
influence of chronic hypoxia on oxidative phenotype in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: in addition to chronic airflow obstruction, patients with chronic obstructive pulmonary disease (copd) suffer from skeletal muscle dysfunction which is a prominent and disabling feature and also an independent determinant of survival. muscular impairment involves loss of muscle oxidative phenotype (oxphen: a slow-to-fast shift in fibre types and reduced oxidative capacity). since hypoxia obviously is a key feature of copd, the aim of this study is to elucidate the role of hypoxia in loss of muscle oxphen. thus, oxphen and expression levels of its key regulators will be determined in the baseline biopsies for association with the degree of hypoxemia. in addition, expression levels of the key oxphen regulators will be measured in pre/post exercise biopsies.


Eligibility criteria:
inclusion criteria: * diagnosis of copd confirmed according to gold score. * hypoxemia group: resting arterial pao2 \<55 mmhg. * normoxemia group : resting arterial pao2 \> 67 mmhg exclusion criteria: * unstable cardiorespiratory status (acute respiratory failure) * oxygen treatment started * inclusion in a pulmonary rehabilitation program in the last 6 months * anticoagulant treatment

Keywords: chronic obstructive pulmonary disease muscle biopsy chronic hypoxia oxyphen oxydative phenotype exercise
n-acetylcysteine to reduce ischemia/reperfusion injury in liver resection

Conditions: Hepatectomy; Reperfusion Injury

Summary: study hypothesis: n-acetylcysteine (nac) can reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping.

one of the most important factors in the pathophysiology of liver dysfunction after hepatic surgery is the cellular damage derived from the interruption of blood flood with reperfusion of the organ. n-acetylcysteine (nac) has proved beneficial in several conditions involving oxidative damage. this study investigates the effects of nac to reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping. methods: 46 asa ii-iii patients scheduled to undergo liver resection where randomised to receive nac (initial dose: 150 mg/kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion) or placebo in a phase iv clinical trial. blood, hepatic and urinary markers were obtained at basal status and 1, 3 and 24 h post final reperfusion.

Eligibility criteria:
inclusion criteria: * hepatectomy exclusion criteria: * asa 4 * cirrhosis * creatinine \> 1.2 mg/dl * associate surgery (pancreatic or splenectomy) * intraoperative bleeding \> 2 l. * active infection of inflammatory disease

Keywords: acetylcysteine
microbial basis of systemic malodor and "people allergic to me" conditions

Conditions: Nutritional and Metabolic Diseases

Summary: the purpose of this study is to identify microbial signatures associated with remission and recurrence of idiopathic malodor and patm conditions.

human odorprints, mostly owing to the microbiome, have proven their value as biomarkers of health and environmental exposures. in recent years, microbial networks responsible for localized malodors such as halitosis or axillary odor have been mapped by using next generation sequencing approaches. intestinal microbes responsible for psychologically debilitating systemic malodor (whole-body and extraoral halitosis), however, remain to be identified. even a relatively straightforward disorder of choline metabolism trimethylaminuria (tmau) is thought to exhibit complex host-gene microbiome interactions and has not been sufficiently studied. proposed controlled pilot study aims to explore the dynamics of microbial communities in remission and flare-up periods. better knowledge of the important aspects of disease fluctuation should enhance patient care and, combined with our prior data, will help to develop new therapies and treatments.

Eligibility criteria:
inclusion criteria: * idiopathic malodor or patm symptoms experienced over a period of several months or years * able to read and understand the study information * willing and able to comply with questionnaires, nutritional recommendations, and other study procedures exclusion criteria: * consistent inability to communicate and process things related to their symptoms * consistent inability to distinguish physical symptoms from pure emotional reactions * lack of motivation to start feeling better

Keywords: systemic malodor body odor bad breath patm microbiome tmau malabsorption dysbiosis
prevalence of transient global amnesia in obstructive sleep apnea syndrome

Conditions: Transient Global Amnesia

Summary: amnesic stroke is an amnestic syndrome lasting less than 24 hours characterized by the occurrence of anterograde amnesia often associated with retrograde amnesia, the pathophysiology of which is still poorly understood at present. a recent study on a small sample size (n=29) highlighted an association between obstructive sleep apnea syndrome and amnesic stroke. our study seeks to confirm or refute these results on a larger cohort (n=200-250). a better understanding of the pathophysiological processes involved would open up new therapeutic avenues.


Eligibility criteria:
inclusion criteria: * adult patients seen for consultation in the neuropsychology department of strasbourg university hospital between march 1, 2015 and december 31, 2021 following an episode of amnestic stroke meeting the hodges and warlow criteria: * the stroke must have been documented and reported by a competent witness present during the stroke. * anterograde amnesia during the stroke. * absence of vigilance, personality, and cognitive disorders other than memory disorders (aphasia, apraxia, etc.). * absence of focal neurological symptoms during the episode and its aftermath. * absence of epileptic manifestations. * resolution of the episode in less than 24 hours. * exclusion of patients with a history of recent head trauma or active epilepsy (undergoing regular treatment or having experienced a seizure in the last 2 years). * subjects who have not expressed opposition to the reuse of their data for scientific research purposes. exclusion criteria: * patients who have expressed opposition to the retrospective reuse of their data for scientific research purposes. * patients with active epilepsy * patients with recent head trauma * patients with an mms \< or equal to 25 * subject under guardianship or curatorship * subject under judicial protection

Keywords: transient global amnesia sleep apnea syndrome
a study to evaluate the safety and tolerability of qr-1123 in subjects with autosomal dominant retinitis pigmentosa due to the p23h mutation in the rho gene

Conditions: Autosomal Dominant Retinitis Pigmentosa; Eye Diseases; Eye Diseases, Hereditary; Retinal Dystrophies; Retinal Disease; Retinitis; Vision Tunnel; Vision Disorders

Summary: this study evaluates the safety, tolerability and efficacy of qr-1123 injection in the eye (intravitreal; ivt) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.

qr-1123 is an antisense oligonucleotide, designed to specifically target the mutant p23h messenger ribonucleic acid (mrna) in order to reduce the expression of the p23h protein selectively, while preserving expression of the wild type (wt) rhodopsin (rho) protein. it is hypothesized that the reduction of mutant p23h mrna will reduce the deleterious effects of the dominant-negative protein and should result in increased function of wt rhodopsin protein in photoreceptors. restoration of wt rho function is expected to improve vision in patients with adrp due to the p23h mutation. the study will comprise up to 8 single dose and repeat dose cohorts. prior to initiating a higher single dose cohort and/or prior to initiating repeat dose cohort(s), available safety and efficacy data will be reviewed by the dmc. in the single dose cohorts subjects will receive a single, unilateral ivt injection of qr-1123 in an open label fashion. in the repeat dose cohorts subjects will be randomized to receive either a unilateral ivt injection of qr-1123 every 3 months or a unilateral sham procedure every 3 months, in a double masked fashion. subjects will be followed for safety, tolerability and efficacy for a total period of 12 months.

Eligibility criteria:
main inclusion criteria: 1. male or female, ≥ 18 years of age. 2. clinical presentation consistent with adrp, based on ophthalmic examinations. 3. impairment on vf in the opinion of the investigator, as determined by perimetry. 4. a molecular diagnosis of autosomal dominant form of rp with the p23h mutation in the rho gene, based on genetic analysis. 5. a clear ocular media and adequate pupillary dilation to permit good quality fundus imaging, as assessed by the investigator. main exclusion criteria: 1. presence of additional pathogenic mutations in genes (other than the p23h mutation in the rho gene) associated with inherited retinal degenerative diseases or syndromes, based on genetic analysis (eg, usher syndrome, leber congenital amaurosis, etc). 2. presence of any significant ocular or non-ocular disease/disorder (including medication and laboratory test abnormalities) which, in the opinion of the investigator and with concurrence of the medical monitor, may either put the subject at risk because of participation in the study, may influence the results of the study, or the subject's ability to participate in the study.

Keywords: adrp retinitis pigmentosa p23h mutation rhodopsin antisense oligonucleotide ivt autosomal dominant